Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease

Ha My T. Vy; Bridget M. Lin; Faris F. Gulamali; Charles Kooperberg; Mariaelisa Graff; Jenny Wong; Kirk N. Campbell; Tara C. Matise; Josef Coresh; Fridtjof Thomas; Alexander P. Reiner; Rami Nassir; Peter F. Schnatz; Tanya Johns; Steven Buyske; Christopher Haiman; Richard Cooper; Ruth J.F. Loos; Carol R. Horowitz; Orlando M. Gutierrez; Ron Do; Nora Franceschini; Girish N. Nadkarni

doi:10.2215/CJN.03610322

Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease

Ha My T. Vy, Bridget M. Lin, Faris F. Gulamali, Charles Kooperberg, Mariaelisa Graff, Jenny Wong, Kirk N. Campbell, Tara C. Matise, Josef Coresh, Fridtjof Thomas, Alexander P. Reiner, Rami Nassir, Peter F. Schnatz, Tanya Johns, Steven Buyske, Christopher Haiman, Richard Cooper, Ruth J.F. Loos, Carol R. Horowitz, Orlando M. GutierrezRon Do, Nora Franceschini, Girish N. Nadkarni

Medicine

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	1522-1525
Number of pages	4
Journal	Clinical Journal of the American Society of Nephrology
Volume	17
Issue number	10
DOIs	https://doi.org/10.2215/CJN.03610322
State	Published - Oct 2022

ASJC Scopus subject areas

Epidemiology
Critical Care and Intensive Care Medicine
Nephrology
Transplantation

Access to Document

10.2215/CJN.03610322

Cite this

Vy, H. M. T., Lin, B. M., Gulamali, F. F., Kooperberg, C., Graff, M., Wong, J., Campbell, K. N., Matise, T. C., Coresh, J., Thomas, F., Reiner, A. P., Nassir, R., Schnatz, P. F., Johns, T., Buyske, S., Haiman, C., Cooper, R., Loos, R. J. F., Horowitz, C. R., ... Nadkarni, G. N. (2022). Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology, 17(10), 1522-1525. https://doi.org/10.2215/CJN.03610322

Vy, HMT, Lin, BM, Gulamali, FF, Kooperberg, C, Graff, M, Wong, J, Campbell, KN, Matise, TC, Coresh, J, Thomas, F, Reiner, AP, Nassir, R, Schnatz, PF, Johns, T, Buyske, S, Haiman, C, Cooper, R, Loos, RJF, Horowitz, CR, Gutierrez, OM, Do, R, Franceschini, N & Nadkarni, GN 2022, 'Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease', Clinical Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 1522-1525. https://doi.org/10.2215/CJN.03610322

@article{5c89eaec82ef4ee0b2897a601fe4edb4,

title = "Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease",

author = "Vy, {Ha My T.} and Lin, {Bridget M.} and Gulamali, {Faris F.} and Charles Kooperberg and Mariaelisa Graff and Jenny Wong and Campbell, {Kirk N.} and Matise, {Tara C.} and Josef Coresh and Fridtjof Thomas and Reiner, {Alexander P.} and Rami Nassir and Schnatz, {Peter F.} and Tanya Johns and Steven Buyske and Christopher Haiman and Richard Cooper and Loos, {Ruth J.F.} and Horowitz, {Carol R.} and Gutierrez, {Orlando M.} and Ron Do and Nora Franceschini and Nadkarni, {Girish N.}",

note = "Funding Information: S. Buyske reports consultancy agreements with Advanced Infrastructure Design, Inc. K.N. Campbell reports consultancy agreements with Calliditas, Goldfinch Bio, Mallinckrodt Pharmaceuticals, Travere, and Vertex; research funding from Aurinia, Goldfinch Bio, and Mallinckrodt Pharmaceuticals; an advisory or leadership role for the medical advisory board of the National Kidney Foundation of Greater New York and the Nephcure Foundation; and board memberships for the National Kidney Foundation and the Nephcure Foundation. J. Coresh reports ownership interest in Healthy.io; consultancy agreements with Healthy.io and SomaLogic; research funding from the National Institutes of Health and the National Kidney Foundation (which receives industry support); and an advisory or leadership role for Healthy.io and the National Kidney Foundation. R. Do reports consultancy agreements with Pensieve Health and Variant Bio; ownership interest in Pensieve Health; and research funding from AstraZeneca and Goldfinch Bio. N. Franceschini reports serving as the Women{\textquoteright}s Health Initiative Vice-Chair of the Ancillary Committee and a National Heart, Lung, and Blood Institute TOPMed kidney working group convener and reports serving on the editorial board of American Journal of Physiology-Renal Physiology, the editorial board of Contemporary Clinical Trials, and the Women{\textquoteright}s Health Initiative Publication and Presentation Committee. O.M. Gutierrez reports consultancy agreements with QED; research funding from Amgen and GlaxoSmithKline; honoraria from Akebia, Amgen, Ardelyx, AstraZeneca, and Reata; and serving as an associate editor of CJASN. R. Loos reports consultancy agreements with Regen-eron and serving as a board member of the European Association of the Study of Diabetes. G.N. Nadkarni reports consultancy agreements with AstraZeneca, Daiichi Sankyo, GLG Consulting, Qiming Capital, Reata, Renalytix, Siemens Healthineers, and Variant Bio; equity in Data2Wisdom LLC, Doximity, Nexus iConnect, Renaly-tix, and Verici; equity in Pensieve Health as a cofounder; research funding from Renalytix; honoraria from Daiichi Sankyo; patents or royalties from Renalytix; an advisory or leadership role for Renalytix; and speakers bureau for Daiichi Sankyo. P.F. Schnatz reports ownership interest in Evertec Inc., First Interstate Bancsystem Inc., Heico Corp., Mastercard Inc., MBIA Inc., and Block Inc. and an advisory or leadership role for Association of Colposcopy and Cervical Pathology and FaithCare, Inc. F. Thomas reports research funding from Relypsa-Vifor Pharma Inc. and serving as an associate editor of Journal of Statistical Computation and Simulation, Taylor and Francis (no reimbursement). F. Thomas{\textquoteright}s spouse serves as an associate editor for Journal of Clinical Oncology (the flagship journal of the American Society for Clinical Oncology: 5-year term from November 1, 2021 to October 31, 2026; contract is with the American Society for Clinical Oncology). All remaining authors have nothing to disclose. Funding Information: This work was supported National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK127139.",

year = "2022",

month = oct,

doi = "10.2215/CJN.03610322",

language = "English (US)",

volume = "17",

pages = "1522--1525",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "10",

}

TY - JOUR

T1 - Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease

AU - Vy, Ha My T.

AU - Lin, Bridget M.

AU - Gulamali, Faris F.

AU - Kooperberg, Charles

AU - Graff, Mariaelisa

AU - Wong, Jenny

AU - Campbell, Kirk N.

AU - Matise, Tara C.

AU - Coresh, Josef

AU - Thomas, Fridtjof

AU - Reiner, Alexander P.

AU - Nassir, Rami

AU - Schnatz, Peter F.

AU - Johns, Tanya

AU - Buyske, Steven

AU - Haiman, Christopher

AU - Cooper, Richard

AU - Loos, Ruth J.F.

AU - Horowitz, Carol R.

AU - Gutierrez, Orlando M.

AU - Do, Ron

AU - Franceschini, Nora

AU - Nadkarni, Girish N.

N1 - Funding Information: S. Buyske reports consultancy agreements with Advanced Infrastructure Design, Inc. K.N. Campbell reports consultancy agreements with Calliditas, Goldfinch Bio, Mallinckrodt Pharmaceuticals, Travere, and Vertex; research funding from Aurinia, Goldfinch Bio, and Mallinckrodt Pharmaceuticals; an advisory or leadership role for the medical advisory board of the National Kidney Foundation of Greater New York and the Nephcure Foundation; and board memberships for the National Kidney Foundation and the Nephcure Foundation. J. Coresh reports ownership interest in Healthy.io; consultancy agreements with Healthy.io and SomaLogic; research funding from the National Institutes of Health and the National Kidney Foundation (which receives industry support); and an advisory or leadership role for Healthy.io and the National Kidney Foundation. R. Do reports consultancy agreements with Pensieve Health and Variant Bio; ownership interest in Pensieve Health; and research funding from AstraZeneca and Goldfinch Bio. N. Franceschini reports serving as the Women’s Health Initiative Vice-Chair of the Ancillary Committee and a National Heart, Lung, and Blood Institute TOPMed kidney working group convener and reports serving on the editorial board of American Journal of Physiology-Renal Physiology, the editorial board of Contemporary Clinical Trials, and the Women’s Health Initiative Publication and Presentation Committee. O.M. Gutierrez reports consultancy agreements with QED; research funding from Amgen and GlaxoSmithKline; honoraria from Akebia, Amgen, Ardelyx, AstraZeneca, and Reata; and serving as an associate editor of CJASN. R. Loos reports consultancy agreements with Regen-eron and serving as a board member of the European Association of the Study of Diabetes. G.N. Nadkarni reports consultancy agreements with AstraZeneca, Daiichi Sankyo, GLG Consulting, Qiming Capital, Reata, Renalytix, Siemens Healthineers, and Variant Bio; equity in Data2Wisdom LLC, Doximity, Nexus iConnect, Renaly-tix, and Verici; equity in Pensieve Health as a cofounder; research funding from Renalytix; honoraria from Daiichi Sankyo; patents or royalties from Renalytix; an advisory or leadership role for Renalytix; and speakers bureau for Daiichi Sankyo. P.F. Schnatz reports ownership interest in Evertec Inc., First Interstate Bancsystem Inc., Heico Corp., Mastercard Inc., MBIA Inc., and Block Inc. and an advisory or leadership role for Association of Colposcopy and Cervical Pathology and FaithCare, Inc. F. Thomas reports research funding from Relypsa-Vifor Pharma Inc. and serving as an associate editor of Journal of Statistical Computation and Simulation, Taylor and Francis (no reimbursement). F. Thomas’s spouse serves as an associate editor for Journal of Clinical Oncology (the flagship journal of the American Society for Clinical Oncology: 5-year term from November 1, 2021 to October 31, 2026; contract is with the American Society for Clinical Oncology). All remaining authors have nothing to disclose. Funding Information: This work was supported National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK127139.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85139527988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139527988&partnerID=8YFLogxK

U2 - 10.2215/CJN.03610322

DO - 10.2215/CJN.03610322

M3 - Letter

C2 - 35948364

AN - SCOPUS:85139527988

SN - 1555-9041

VL - 17

SP - 1522

EP - 1525

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 10

ER -

Genome-Wide Epistatic Interaction between DEF1B and APOL1 High-Risk Genotypes for Chronic Kidney Disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this